Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
46 hedge funds and large institutions have $9.23M invested in Clearside Biomedical in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 8 closing their positions.
258% more call options, than puts
Call options by funds: $118K | Put options by funds: $33K
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
35% more capital invested
Capital invested by funds: $6.82M → $9.23M (+$2.41M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 45 → 46 (+1)
0% more ownership
Funds ownership: 0.84% → 0.84% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$115K |
| 2 |
Renaissance Technologies
New York
|
+$106K |
| 3 |
N
Natixis
Paris,
France
|
+$45.2K |
| 4 |
Millennium Management
New York
|
+$32K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIC
Water Island Capital
New York
|
-$71.8K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$62.4K |
| 3 |
Two Sigma Advisers
New York
|
-$54.7K |
| 4 |
S
SignatureFD
Atlanta,
Georgia
|
-$47.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$42.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$42.6K | -2,987 | -100% |
|
|
SWP
52
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$27.4K | -2,096 | Closed |
|
53
Acadian Asset Management
Boston,
Massachusetts
| – | -$15K | -1,169 | Closed |
|
54
Group One Trading
Chicago,
Illinois
| – | -$1.51K | -106 | Closed |
|
|
HGERS
55
Householder Group Estate & Retirement Specialist
Scottsdale,
Arizona
| – | +$371 | +26 | New |
|
CLSD Hedge Fund Activity: Q4 2023 in Review
46 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2023, worth a combined $9.23M — up 35% from $6.82M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CLSD positions and 8 closed out — a net gain of 1 holder — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $115K. The largest seller was Water Island Capital, exiting entirely with an estimated $71.8K sold.
- 46 institutional investors held Clearside Biomedical (CLSD) as of Q4 2023, up from 45 in Q3 2023.
- Funds reported $9.23M of Clearside Biomedical stock for Q4 2023, up 35% quarter-over-quarter.
- 9 funds opened new Clearside Biomedical positions in Q4 2023 and 8 closed out, a net change of +1 holder.
- The largest Clearside Biomedical buyer in Q4 2023 was Morgan Stanley, an estimated $115K added.
- The largest Clearside Biomedical seller in Q4 2023 was Water Island Capital, an estimated $71.8K sold.
Based on aggregated 13F filings for Q4 2023.